212 related articles for article (PubMed ID: 20842591)
81. Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma.
Sperring CP; Argenziano MG; Savage WM; Teasley DE; Upadhyayula PS; Winans NJ; Canoll P; Bruce JN
Neurooncol Adv; 2023; 5(1):vdad044. PubMed ID: 37215957
[TBL] [Abstract][Full Text] [Related]
82. Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
Castelli B; Fonte C; Guidi M; Tellini M; Di Nicola M; Iacono A; Buccoliero AM; Greto D; Genitori L; Sardi I
Front Oncol; 2023; 13():1244628. PubMed ID: 37799478
[TBL] [Abstract][Full Text] [Related]
83. The Treatment of Malignant Gliomas.
Gilbert MR; Loghin M
Curr Treat Options Neurol; 2005 Jul; 7(4):293-303. PubMed ID: 15967092
[TBL] [Abstract][Full Text] [Related]
84. Recurrent Glioblastoma: Where we stand.
Roy S; Lahiri D; Maji T; Biswas J
South Asian J Cancer; 2015; 4(4):163-73. PubMed ID: 26981507
[TBL] [Abstract][Full Text] [Related]
85. Novel "T-Dimension" Therapies for Pediatric Optic Pathway Glioma: A Timely, Targeted, and Tailored Treatment Trend.
Giotta Lucifero A; Elbabaa SK; Baldoncini M; Bruno N; Savasta S; Marseglia GL; Luzzi S
Pediatr Neurosurg; 2022; 57(3):161-174. PubMed ID: 35588700
[TBL] [Abstract][Full Text] [Related]
86. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.
Birzu C; French P; Caccese M; Cerretti G; Idbaih A; Zagonel V; Lombardi G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375286
[TBL] [Abstract][Full Text] [Related]
87. Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.
Sener U; Islam M; Webb M; Kizilbash SH
Neurooncol Adv; 2024; 6(1):vdae039. PubMed ID: 38596714
[TBL] [Abstract][Full Text] [Related]
88. Recent innovations in the management of low-grade gliomas.
Hafeez S; Cavaliere R
Curr Treat Options Neurol; 2012 Aug; 14(4):369-80. PubMed ID: 22798081
[TBL] [Abstract][Full Text] [Related]
89. Clinical, imaging, and molecular features of radiation-induced glioblastomas developing more than 20 years after radiation therapy for intracranial germinomatous germ cell tumor: illustrative cases.
Tsukamoto Y; Natsumeda M; Takahashi H; Ueno A; Sakai K; Shida K; Seto H; Saito T; Shibuma S; Nakayama Y; Tanaka Y; Nakano T; Ohta A; Maruyama K; Okada M; Eda T; Seki Y; Yoneoka Y; Shimizu H; Okamoto K; Kakita A; Oishi M
J Neurosurg Case Lessons; 2023 Oct; 6(16):. PubMed ID: 37870755
[TBL] [Abstract][Full Text] [Related]
90. Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab.
Katz A; Calabrich A; Dos Santos Fernandes G; Sakis Novis YA
Case Rep Oncol; 2009 Mar; 2(1):57-60. PubMed ID: 20740146
[TBL] [Abstract][Full Text] [Related]
91. Nonsurgical treatment of recurrent glioblastoma.
Gallego O
Curr Oncol; 2015 Aug; 22(4):e273-81. PubMed ID: 26300678
[TBL] [Abstract][Full Text] [Related]
92. Corrigendum: Bevacizumab-Irinotecan combination therapy in recurrent low-grade glioma, previously treated with chemo-radiotherapy: a case report.
Castelli B; Fonte C; Guidi M; Tellini M; Di Nicola M; Iacono A; Buccoliero AM; Greto D; Genitori L; Sardi I
Front Oncol; 2024; 14():1372295. PubMed ID: 38361778
[TBL] [Abstract][Full Text] [Related]
93. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).
Taylor J; Gerstner ER
Curr Treat Options Neurol; 2013 Jun; 15(3):328-37. PubMed ID: 23417315
[TBL] [Abstract][Full Text] [Related]
94. Primary brain tumors in the elderly population.
Brandes AA; Franceschi E
Curr Treat Options Neurol; 2011 Aug; 13(4):427-35. PubMed ID: 21484262
[TBL] [Abstract][Full Text] [Related]
95. First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?
van der Meulen M; Mason WP
Neurooncol Pract; 2022 May; 9(3):163-164. PubMed ID: 35601972
[No Abstract] [Full Text] [Related]
96. Author Correction: Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements.
Brüningk SC; Peacock J; Whelan CJ; Brady-Nicholls R; Yu HM; Sahebjam S; Enderling H
Sci Rep; 2022 Mar; 12(1):4441. PubMed ID: 35292722
[No Abstract] [Full Text] [Related]
97. A new targeted therapy for low-grade glioma.
O'Leary K
Nat Med; 2023 Jun; ():. PubMed ID: 37308794
[No Abstract] [Full Text] [Related]
98. Pseudoprogression in low-grade glioma.
Slater JM; Shih HA
Transl Cancer Res; 2019 Dec; 8(Suppl 6):S580-S584. PubMed ID: 35117135
[No Abstract] [Full Text] [Related]
99. Stereotactic Radiosurgery for the Treatment of Recurrent High-grade Gliomas: Long-term Follow-up.
Sallabanda K; Yañez L; Sallabanda M; Santos M; Calvo FA; Marsiglia H
Cureus; 2019 Dec; 11(12):e6527. PubMed ID: 31911881
[TBL] [Abstract][Full Text] [Related]
100. Anaplastic astrocytoma.
Grimm SA; Chamberlain MC
CNS Oncol; 2016 Jul; 5(3):145-57. PubMed ID: 27230974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
